超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國(guó)Glycosan BioSystems?

?

?

?
Glycosan BioSystems, a privately held life-sciences technology company, is based in Salt Lake City, Utah, where the company was founded by Glenn Prestwich, William Tew, and Anna Scott in January 2006. The company received startup support from the Centers of Excellence Program for innovative research in Utah and from the University of Utah, then closed its first round of investment in May 2007. Glycosan’s patent-pending Extracel? technology was developed by the Center for Therapeutic Biomaterials at the University of Utah. Glycosan is located in Research Park adjacent to the university.

Intellectual Property
Glycosan BioSystems holds exclusive worldwide rights to a patent estate, which was licensed from the University of Utah Research Foundation with broad claims to product chemical composition, method of crosslinking, method of preparation, and use of the synthetic extracellular matrix (sECM).

The exclusive sECM technology behind Glycosan’s Extracel? product line makes several specific applications possible, including:

in vitro three-dimensional cell culture
in vitro and in vivo animal models to screen for drug efficacy, safety, and toxicology
reagents for tissue and cell preservation
personal-care products
Glycosan also holds a co-exclusive license for tissue engineering and cell-therapy applications of Extracel?.

Management Team
William P. Tew, Cofounder, President, and CEO
Dr. Tew is an entrepreneurial executive with extensive experience in life sciences, biopharmaceuticals, and university technology licensing. His background in biochemistry and medical research successfully converted to the development production expertise he brings to Glycosan. As founder of Chesapeake Biological Laboratories, he served as chairman and CEO for almost two decades (1981-1999), developing and manufacturing bulk pharmaceuticals, parenteral drugs, and medical devices in compliance with FDA and cGMP regulations. He also oversaw the design, validation, and operation of sterile filling and packing facilities and implemented reliable ISO quality-management systems.

Contact Dr. Tew: wptew@glycosan.com

Glenn D. Prestwich, PhD, Cofounder and CSO
As University of Utah’s Presidential Professor of Medicinal Chemistry, Dr. Prestwich has mentored more than 150 students and post-doctorate candidates over the past thirty years. During that time, he has earned broad industry recognition for award-winning research, product innovation, and entrepreneurship with 520 published, peer-reviewed research papers. He directed the New York State Center of Biotechnology at the University of Stony Brook as well as the Center for Cell Signaling, a Utah Center of Excellence for the commercialization of new pharmaceutical technologies. He was chief scientific officer (CSO) and cofounder of Echelon Biosciences, senior scientific advisor (SSA) of Sentryx Animal Care, and SSA and SAB for Carbylan BioSurgery. Today Dr. Prestwich directs a new Center for Excellence, the Center for Therapeutic Biomaterials, as Glycosan BioSystem’s CSO.

Contact Dr. Prestwich: gdprestwich@glycosan.com

Thomas Zarembinski, PhD, MBA, Director of Business Development
With a doctorate in plant molecular biology, a bachelor’s in biochemistry, an MBA, and five years of experience in the pharmaceutical industry, Dr. Zarembinkski was uniquely prepared to assume the role of director of business development for Glycosan BioSystems. He draws on his experience as senior scientist at Prolexys Pharmaceuticals, where he managed the asthma high-throughput drug-discovery effort and played a key role in establishing the company’s high-throughput protein production and purification pipeline.

?